Results 1 to 10 of about 96,949 (272)
Role of biofilm formation and antimicrobial resistance in urogenital Haemophilus influenzae isolates [PDF]
BMC MicrobiologyBackground Haemophilus influenzae (Hi) is increasingly detected in genital infections in humans and linked to septic abortion. We aimed to characterize 123 non-capsulated (non-typeable) Hi isolates from genital sites in women and investigate their ...
Nouria Belkacem +4 more
doaj +2 more sources
Multi-Antigen Protein Vaccine Confers Protection in a Murine Model Against Intranasal Haemophilus influenzae Challenge [PDF]
VaccinesBackground: Non-typeable Haemophilus influenzae (NTHi) is a major cause of acute respiratory tract infections and chronic airway disease, despite its clinical importance, no licensed vaccine is available, largely due to the extensive genetic and ...
Nouria Belkacem +2 more
doaj +2 more sources
Haemophilus influenzae and the lung (Haemophilus and the lung) [PDF]
Clinical and Translational Medicine, 2012 Haemophilus influenzae is present as a commensal organism in the nasopharynx of most healthy adults from where it can spread to cause both systemic and respiratory tract infection.
Paul King
doaj +3 more sources
A review of the DTaP-IPV-HB-PRP-T Hexavalent vaccine in pediatric patients
Expert Review of Vaccines, 2023 Introduction Hexaxim is a hexavalent vaccine approved as primary and booster vaccination in infants 6 weeks and older, protecting against diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B and Haemophilus influenzae type b.
Andrew Dakin +2 more
doaj +1 more source
Haemophilus influenzae type b (Hib) seroprevalence in France: impact of vaccination schedules
BMC Infectious Diseases, 2021 Background Haemophilus influenzae serotype b (Hib) conjugate vaccine was introduced in France in 1992 as a 3 + 1 scheme at 2, 3, and 4 months (primary vaccination) with a booster at the age of 16–18 months. The vaccination was simplified in 2013 to a 2 +
Eva Hong +6 more
doaj +1 more source
The rapid rebound of invasive meningococcal disease in France at the end of 2022
Journal of Infection and Public Health, 2023 Background: Invasive meningococcal disease (IMD) cases declined upon the implementation of non-pharmaceutical measures to control the COVID-19 pandemic. A rebound in IMD cases was feared upon easing these measures.
Samy Taha +6 more
doaj +1 more source
Haemophilus endocarditis [PDF]
Postgraduate Medical Journal, 1981 Summary Two cases are presented of Haemophilus endocarditis in patients with presumed normal valves. One case was due to H. influenzae presenting as a typical case of infective endocarditis and the other was due to H. para-influenzae presenting as an acute pyrexia of unknown origin. The difficulties in making the diagnosis
A M, Emmerson +2 more
openaire +2 more sources
npj Vaccines, 2022 Since January 2018, mandatory vaccination against meningococci serogroup C has been implemented in France for children
Samy Taha +2 more
doaj +1 more source
Product review on the IMD serogroup B vaccine Bexsero®
Human Vaccines & Immunotherapeutics, 2022 Bexsero® is a multicomponent vaccine composed of four major proteins of Neisseria meningitidis: the fHbp, NHBA, NadA and PorA. This vaccine was licensed against invasive meningococcal disease (IMD) due to serogroup B isolates.
Ala-Eddine Deghmane, Muhamed-Kheir Taha
doaj +1 more source
Journal of Public Health in Africa, 2022 Introduction. Before the introduction of vaccination to protect children from pneumonia, Streptococcus pneumoniae and Haemophilus influenzae type B (HiB) were the most frequent aetiological agents causing bacterial pneumonia in children under five years ...
Chukwuemeka Onwuchekwa +6 more
doaj +1 more source